Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04337359
Expanded Access Status : No longer available
First Posted : April 7, 2020
Last Update Posted : January 26, 2021
Novartis is the Marketing Authorization Holder for Jakavi outside the US.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:

The purpose of this Cohort Treatment Plan is to allow access to ruxolitinib for eligible patients diagnosed with severe/very severe COVID-19 illness. The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

The requesting Treating Physician submitted a request for access to drug (often referred to as Compassionate Use) to Novartis which was reviewed and approved by the medical team experienced with the drug and indication.

Please refer to the latest Investigator's Brochure (IB) or approved label for overview of ruxolitinib including: non-clinical and clinical experience, risk and benefits. Novartis will continue to provide any new safety information to the Treating Physician as they emerge.

Condition or disease Intervention/treatment
Severe/Very Severe COVID-19 Illness Drug: Ruxolitinib

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Intermediate-size Population
Official Title: Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness

Intervention Details:
  • Drug: Ruxolitinib
    5 mg. Tablet
    Other Name: Jakavi

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years to 90 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients eligible for inclusion in this Treatment Plan have to meet all of the following criteria:

Written patient informed consent or assent must be obtained prior to start of treatment.

  • Patients aged ≥ 6 years
  • Patients clinically diagnosed with SARS-CoV-2 infection, either through positive serum antibodies (IgM or IgG); or by PCR; or by other approved diagnostic methodology. Patients with presumptive diagnosis of COVID-19 (other respiratory causes ruled out and SARS-CoV-2 test pending) may be included.
  • Adult and adolescent patients (≥12years), who meet one of the below criteria

    • Respiratory frequency ≥ 30/min
    • Oxygen saturation ≤ 93% on room air (FiO2=0.21)
    • Arterial oxygen partial pressure (PaO2)/ fraction of inspired oxygen (FiO2) <300mmHg(1mmHg=0.133kPa) (corrective formulation should be used for higher altitude regions (over 1000m).


-- Patients with lung imaging showing pulmonary infiltrates (chest X-ray or CT scan)

Pediatric patients (≥6-<12 years) who meet one of the below criteria (where appropriate):

  • Shortness of breath
  • Oxygen saturation <92% on room air (Fi)2=0.21)
  • Labored breathing (e.g. wheezing, flaring of nostrils, three concave sign), cyanosis, intermittent apnea.
  • Lethargy or convulsions
  • Refusal to eat or difficulty with feeding; signs of dehydration

Exclusion Criteria:

  • Patients eligible for this Treatment Plan must not meet any of the following criteria:
  • History of hypersensitivity to any drugs or metabolites of similar chemical classes as ruxolitinib
  • Presence of severely impaired renal function defined by serum creatinine > 2 mg/dL (>176.8 μmol/L), or have estimated creatinine clearance < 30 ml/min measured or calculated by Cockroft Gault equation or calculated by the updated bedside Schwartz equation.
  • Pregnant or nursing (lactating) women.
  • Patients who are NOT able to understand and to comply with treatment instructions and requirements unless health care proxy is able to provide consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04337359

Sponsors and Collaborators
Novartis Pharmaceuticals
Novartis is the Marketing Authorization Holder for Jakavi outside the US.
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals Identifier: NCT04337359    
Other Study ID Numbers: CINC424A2001M
First Posted: April 7, 2020    Key Record Dates
Last Update Posted: January 26, 2021
Last Verified: January 2021
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Corona Virus
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Tract Infections
Pneumonia, Viral
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases